false 2025 Q3 --12-31 0001310488 0001310488 2025-01-01 2025-09-30 0001310488 2025-11-17 0001310488 2025-09-30 0001310488 2024-12-31 0001310488 2025-07-01 2025-09-30 0001310488 2024-07-01 2024-09-30 0001310488 2024-01-01 2024-09-30 0001310488 2023-12-31 0001310488 2024-09-30 0001310488 us-gaap:CommonStockMember 2023-12-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001310488 us-gaap:RetainedEarningsMember 2023-12-31 0001310488 us-gaap:CommonStockMember 2024-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001310488 us-gaap:RetainedEarningsMember 2024-03-31 0001310488 2024-03-31 0001310488 us-gaap:CommonStockMember 2024-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001310488 us-gaap:RetainedEarningsMember 2024-06-30 0001310488 2024-06-30 0001310488 us-gaap:CommonStockMember 2024-12-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001310488 us-gaap:RetainedEarningsMember 2024-12-31 0001310488 us-gaap:CommonStockMember 2025-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001310488 us-gaap:RetainedEarningsMember 2025-03-31 0001310488 2025-03-31 0001310488 us-gaap:CommonStockMember 2025-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001310488 us-gaap:RetainedEarningsMember 2025-06-30 0001310488 2025-06-30 0001310488 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001310488 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001310488 2024-01-01 2024-03-31 0001310488 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001310488 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001310488 2024-04-01 2024-06-30 0001310488 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001310488 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001310488 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001310488 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001310488 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001310488 2025-01-01 2025-03-31 0001310488 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001310488 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001310488 2025-04-01 2025-06-30 0001310488 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001310488 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001310488 us-gaap:CommonStockMember 2024-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001310488 us-gaap:RetainedEarningsMember 2024-09-30 0001310488 us-gaap:CommonStockMember 2025-09-30 0001310488 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001310488 us-gaap:RetainedEarningsMember 2025-09-30 0001310488 2020-05-01 2020-05-06 0001310488 bfnh:MrMerleMember 2025-01-01 2025-09-30 0001310488 bfnh:RichardKaiserMember 2025-09-30 0001310488 bfnh:MrFergusonMember 2025-01-01 2025-09-30 0001310488 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001310488 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001310488 2019-11-01 2019-11-25 0001310488 2025-01-02 2025-01-24 0001310488 2025-01-02 2025-01-27 0001310488 2025-11-01 2025-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-51074

BIOFORCE NANOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Commission file number: 000-53505

Nevada	74-3078125
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

2020 General Booth Blvd., Unit 230 Virginia Beach, VA (principal executive offices)	23454 (Zip Code)

Registrant's telephone number, including area code: (757) 306-6090

Securities registered under Section 12(b) of the Exchange Act:	None

Securities registered under Section 12(g) of the Exchange Act:	Common stock, par value $0.001 per share
	(Title of class)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Non-accelerated filer ☒

Emerging growth company ☐

Accelerated filer ☐

Smaller reporting company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
NONE		NONE		NONE

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: At November 18, 2025 the registrant had outstanding 33,521,755 shares of common stock, par value $0.001 per share.

-i-

TABLE OF CONTENTS

		PAGE
PART I
Item 1.	Condensed Consolidated Unaudited Financial Statements	2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	13
PART II
Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Mining Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	15
	Signatures	15

-1-

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIOFORCE NANOSCIENCES HOLDINGS, INC.

FINANCIAL REPORTS

SEPTEMBER 30, 2025

INDEX TO FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets at September 30, 2025 Unaudited and December 31, 2024	4
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 - Unaudited	5
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 - Unaudited	6
Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024-Unaudited	7
Notes to the Condensed Consolidated Unaudited Financial Statements	8-10

-2-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED


	September 30,			December 31,
	2025			2024
ASSETS
Current Assets
Cash	$	784		$	862

Total Current Assets		784			862

Total Assets	$	784		$	862

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts Payable and Accrued Expenses	$	10,709		$	8,836
Accrued Board of Directors Compensation		421,800			2,019,517
Due to Related Parties		68,213			274,101

Total Current Liabilities		500,722			2,302,454

Total Liabilities		500,722			2,302,454


Stockholders' Deficit
Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 33,521,755 and 29,271,755 Issued and Outstanding, Respectively		33,522			29,272
Additional Paid-In-Capital		161,760,052			158,789,302
Accumulated Deficit		(162,293,512	)		(161,120,166	)

Total Stockholders' Deficit		(499,938	)		(2,301,592	)

Total Liabilities and Stockholders' Deficit	$	784		$	862

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-3-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Sales	$	-		$	-		$	-		$	-

Cost of Sales		-			-			-			-

Gross Profit		-			-			-			-

Operating Expenses
Board of Directors Compensation		105,750			105,750			317,250			317,250
General and Administrative		10,165			16,274			54,903			50,027

Total Expenses		115,915			122,024			372,153			367,277

Loss from Operations Before Loss on Liability Settlement		(115,915	)		(122,024	)		(372,153	)		(367,277	)

Loss on Liability Settlement		-			-			(801,193	)		-

Net Loss for the Period	$	(115,915	)	$	(122,024	)	$	(1,173,346	)	$	(367,277	)

Weighted Average Number of Common Shares - Basic and Diluted		33,521,755			29,271,755			33,101,425			29,271,755

Net Loss for the Period Per Common Shares - Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.04	)	$	(0.01	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-4-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED


For the Nine Months Ended September 30,	2025			2024

Cash Flows from Operating Activities

Net Loss for the Period	$	(1,173,346	)	$	(367,277	)
Adjustments to reconcile net loss for the period to net cash used in operating activities:
Loss on Liability Settlement		801,193			-

Changes in Assets and Liabilities:
Accounts Payable and Accrued Expenses		1,873			3,612
Accrued Board of Directors Compensation		316,051			317,250

Net Cash Flows Used In Operating Activities		(54,229	)		(46,415	)

Cash Flows from Investing Activities		-			-

Cash Flows from Financing Activities
Capital Contributions		-			8,075
Proceeds from Related Parties		54,151			39,337

Net Cash Flows Provided by Financing Activities		54,151			47,412

Net Change in Cash		(78	)		997

Cash - Beginning of the Period		862			638

Cash - End of the Period	$	784		$	1,635

Cash Paid During the Period for:
Interest	$	-		$	-
Income Taxes	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-5-

BioForce Nanosciences Holdings, Inc., and Subsidiary

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT FOR THE THREE AND NINE MONTHS

ENDED SEPTEMBER 30, 2025 AND 2024

UNAUDITED


	Common Stock				Additional					Total
	$ 0.001 Par				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Deficit
Balance - January 1, 2024		29,271,755	$	29,272	$	158,781,227	$	(160,629,729	)	$	(1,819,230	)

Net Loss for the Period		-		-		-		(130,813	)		(130,813	)

Balance - March 31, 2024		29,271,755		29,272		158,781,227		(160,760,542	)		(1,950,043	)

Capital Contributions		-		-		75		-			75

Net Loss for the Period		-		-		-		(114,440	)		(114,440	)

Balance - June 30, 2024		29,271,755		29,272		158,781,302		(160,874,982	)		(2,064,408	)

Capital Contributions		-		-		8,000		-			8,000

Net Loss for the Period		-		-		-		(122,024	)		(122,024	)

Balance - September 30, 2024		29,271,755	$	29,272	$	158,789,302	$	(160,997,006	)	$	(2,178,432	)

	Common Stock				Additional					Total
	$ 0.001 Par				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Deficit
Balance - January 1, 2025		29,271,755	$	29,272	$	158,789,302	$	(161,120,166	)	$	(2,301,592	)

Common Stock Issued to Satisfy Liabilities		4,250,000		4,250		2,970,750		-			2,975,000

Net Loss for the Period		-		-		-		(934,650	)		(934,650	)

Balance - March 31, 2025		33,521,755		33,522		161,760,052		(162,054,816	)		(261,242	)

Net Loss for the Period		-		-		-		(122,781	)		(122,781	)

Balance - June 30, 2025		33,521,755		33,522		161,760,052		(162,177,597	)		(384,023	)

Net Loss for the Period		-		-		-		(115,915	)		(115,915	)

Balance - September 30, 2025		33,521,755	$	33,522	$	161,760,052	$	(162,293,512	)	$	(499,938	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

-6-

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

NOTE 1 – Organization & Description of Business

The Company was incorporated in the State of Nevada on December 10, 1999 as Silver River Ventures, Inc. On February 24, 2006, the Company completed the acquisition of BioForce Nanosciences Holdings Inc. (“BioForce”), a Delaware corporation, and changed the corporate name at that time. On May 6, 2020, the Company purchased 100,000 shares of Element Acquisition Corporation for $1,000 which then became a wholly owned subsidiary. On October 15, 2020, the Company’s wholly-owned subsidiary changed its name from Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc, a Wyoming corporation. On December 14, 2021, the Company’s wholly-owned subsidiary changed its name from BioForce Nanosciences Holdings, Inc., a Wyoming corporation to Element Global Inc., a Wyoming corporation. The Company’s mission is to become a leading provider of vitamin, mineral and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges.

NOTE 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated balance sheet has been derived from the December 31, 2024 audited financial statements and the unaudited condensed consolidated financial statements as of September 30, 2025 and 2024, have been prepared in accordance with generally accepted accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited financial statements and related footnotes included in our Annual report on Form 10-K for the year ended December 31, 2024 (the “2024 Annual Report”), filed with the Securities and Exchange Commission (the “SEC”). It is management’s opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for fair condensed consolidated financial statements presentation. Operating results for the three and nine months ended September 30, 2025, are not necessarily indicative of the results of operations expected for the year ending December 31, 2025.

Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of Bioforce Nanosciences Holdings, Inc., and its wholly owned subsidiary, Element Global, Inc., a Wyoming corporation, (the “Company”). All significant inter-company balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Earnings (Loss) per Share

Earnings (loss) per share of common stock are computed in accordance with FASB ASC 260 “Earnings per Share”. Basic earnings (loss) per share are computed by dividing income or loss available to common shareholders by the weighted-average number of common shares outstanding for each period. Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding assuming conversion of all potentially dilutive stock options, warrants and convertible securities, if dilutive. Common stock equivalents that are anti-dilutive are excluded from both diluted weighted average number of common shares outstanding and diluted earnings (loss) per share.

-7-

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

NOTE 2 – Summary of Significant Accounting Policies - continued

Stock-Based Compensation

We account for employee and non-employee stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation—Stock Compensation, which requires all share-based payments, including grants of stock options, to be recognized in the financial statements based on their fair values. The fair value of the equity instrument is charged directly to compensation expense and credited to additional paid-in capital over the period during which services are rendered.

Fair Value of Financial Instruments

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable and accrued liabilities approximate fair value given their short-term nature or effective interest rates.

Revenue Recognition

The Company implemented ASC 606, Revenue from Contracts with Customers. These included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures.

The Company recognizes revenue and cost of goods sold from product sales or services rendered when control of the promised goods are transferred to our clients in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenues when or as the Company satisfies a performance obligation.

NOTE 3 – Recently Issued Accounting Standards

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 4 – Going Concern

The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.

While the Company is attempting to continue operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management believes that the actions presently being taken to further implement the Company’s business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues. During the nine months ended September 30, 2025 due to lack of revenues the officers of the Company paid for all expenses through loans to the Company. This allowed the Company to continue as a going concern.

-8-

BIOFORCE NANOSCIENCES HOLDINGS, INC., AND SUBSIDIARY

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

NOTE 5 – Related Party Transactions

The Company utilizes the services of Yes International Inc., which is controlled by Mr. Richard Kaiser who is a member of the Board of Directors. Yes International provides all services at no cost except for press release wire services and filing fees. For each of the three months ended September 30, 2025 and 2024 the Company paid press release wire services and filing fees a total in the amount of $900 and $700 respectively. For each of the nine months ended September 30, 2025 and 2024 the Company paid press release wire services and filing fees a total in the amount of $2,680 and $700 respectively The Company also currently operates out of Yes International Inc., offices at no cost.

During the nine months ended September 30, 2025 and 2024, two board of directors paid expenses of the Company in the amount of $3,152 and $39,338, respectively. During the nine months ended September 30, 2025, Mr. Merle Ferguson was issued 4,250,000 shares of common stock to reimburse him for accrued compensation and amounts due him totaling $2,173,000. Of this amount Mr. Richard Kaiser allowed Mr. Ferguson to assume $22,154 of his accrued liabilities. Mr. Ferguson also loaned $51,000 to the Company during the nine months ended September 30, 2025. Due to related parties was $68,213 and $274,101 at September 30, 2025 and December 31, 2024, respectively.

NOTE 6 – Stock

Preferred Stock

Preferred stock consists of 100,000,000 shares authorized at $0.001 par value. 10,000,000 of these preferred shares have been separately allocated to Series A Preferred. Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock. At September 30, 2025 and December 31, 2024, there were -0- Series A Preferred shares issued and outstanding.

Common Stock

Common stock consists of 900,000,000 shares authorized at $0.001 par value. On November 25, 2019, the board of directors approved a 5 to 1 reverse split. At September 30, 2025 and December 31, 2024, there were 33,521,755 and 29,271,755 shares issued and outstanding, respectively.

On January 24, 2025 the Board approved the issuance of 4,250,000 shares of common stock to pay Mr. Ferguson for $2,173,000 that was owed to him. On January 27, 2025 when the stock was issued, the market value per share was $0.70 or $2,975,000. The difference of $801,193 is considered a loss on liability settlement and is included in the statement of operations for the nine months ended September 30, 2025.

NOTE 7 – Subsequent Events

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2025 to the date of November 18, 2025 and has determined that it did have a subsequent event. A related party on November 10, 2025, deposited $10,000 into the Company’s bank account to cover the Company's professional fees and other operational expenses.

-9-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with our financial statements and related notes thereto included in Part I, Item 1, above.

Forward Looking Statements

Certain matters discussed herein are forward-looking statements. Such forward-looking statements contained in this Form 10-Q involve risks and uncertainties, including statements as to:

·our future strategic plans

·our future operating results;

·our business prospects;

·our contractual arrangements and relationships with third parties;

·the dependence of our future success on the general economy;

·our possible future financing; and

·the adequacy of our cash resources and working capital.

From time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Such forward-looking statements may be included in, but not limited to, press releases, oral statements made with the approval of an authorized executive officer or in various filings made by us with the Securities and Exchange Commission. Words or phrases "will likely result", "are expected to", "will continue", "is anticipated", "estimate", "project or projected", or similar expressions are intended to identify "forward-looking statements". Such statements are qualified in their entirety by reference to and are accompanied by the above discussion of certain important factors that could cause actual results to differ materially from such forward-looking statements.

The risks identified here are not all inclusive. New risk factors emerge from time to time and it is not possible for management to predict all of such risk factors, nor can it assess the impact of all such risk factors on the company's business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results.

The financial information set forth in the following discussion should be read with the financial statements of BioForce NanoSciences Holdings, Inc. included elsewhere herein.

Business

BioForce Nanosciences Holdings, Inc. (“BioForce or the “Company”) was previously in the business of manufacturing nano-particular measurement devices and molecular printers, but due to a lack of profitability, the subsidiary of the company that owned that technology filed for bankruptcy. That subsidiary and related technology was later bought out of bankruptcy by an unrelated third party. Subsequently, new management came into the Company to pursue a better business model and now the Company’s mission is to become a leading provider of natural vitamins, minerals and other nutritional supplements, powders and beverages, formulated to promote a healthier lifestyle for active individuals in all age ranges. The Company private labels products with key distributors and manufacturing providers.

BioForce entered into the supplement business in or about 2015. These supplements, powders and beverages offer vitamins and minerals to complement a healthy intake of protein and carbohydrates for active individuals and participants in sports.

BioForce is working on its business model and it is in the process of establishing a dynamic marketing campaign to achieve brand awareness of its product offerings to drive business growth through sales of nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online. BioForce currently markets its products through social media and telemarketing. The Company plans to expand marketing efforts with a direct marketing and B2B (Business to Business) sales campaign, with the eventual expectation to expand throughout the entire United States.

The Company proactively seeks to expand its “BioForce Eclipse” nutritional powder for use into households throughout the U.S., and the Company will approach retail stores, including health food and sporting goods stores to create a vendor relationship. During this phase, the Company will continue to try to advance its social media platform with direct online and targeted advertisements to health conscience individuals.

Nutrition retailers, grocery stores, retail pharmacies, and online stores, like Amazon, will be important channels for the Company’s Eclipse product-lines. In The USA, there are thousands of direct outlets like grocery stores, pharmacies, hospitals, department stores, medical clinics, surgery clinics, universities, nursing homes, prisons, and other facilities which are all targets of potential sales of the vitamin and mineral supplemental products.

BioForce Nanosciences Holdings, Inc. sells the BioForce Eclipse powder multivitamin and mineral supplement without non-compete and non-disclosure agreements. The Company currently private labels the powder through a manufacturer located in Virginia. The Company has a Supplier Agreement with this manufacturer that gives the Company non-exclusion rights to market the product. The distributor owns the rights to the formula for this product. If the Company can source product in a more cost-effective way without diminished quality, the Company would evaluate such opportunities when presented. Currently, the distributor who provides the private label powder provides “Consignment Terms,” which allows us to only pay for the product when it is sold.

-10-

The FDA has rules regarding the fitness for consumption of foods as well as vitamins and supplements sold to the public, and those laws apply to our product. However, our product does not require pre-clearance like a drug in order to be sold into the marketplace.

The Company in May 2020, formed a wholly-owned subsidiary, Element Acquisition Corporation, a Wyoming corporation,with unlimited common shares authorized, par value $0.001. Element Acquisition Corporation was formed to pursue potential acquisitions in the media, entertainment, media technology and sports sectors.

The Company on October 15, 2020 changed the name of its wholly-owned subsidiary Element Acquisition Corporation, a Wyoming corporation, to BioForce Nanosciences Holdings, Inc., a Wyoming corporation. Management intends to redomicile BioForce Nanosciences Holdings, Inc., a Nevada corporation, into a Wyoming corporation using its wholly-owned BioForce Nanosciences Holdings, Inc., a Wyoming corporation as the entity for the redomicile corporate action.

On December 14, 2021, the Company changed the name of its wholly-owned subsidiary, BioForce Nanosciences Holdings, Inc., a Wyoming corporation, to its new name, Element Global, Inc.

Memorandum of Understanding ("MOU")

June 02, 2021, Bioforce Nanosciences Holdings, Inc. entered into another Memorandum of Understanding (MOU) with Element Global, Inc. (ELGL), a Utah Corporation. This MOU contemplates a proposed transaction between the entities that provides for BFNH to acquire all of the assets controlled by ELGL. The closing of the transaction is subject to due diligence and the execution of a definitive agreement. As of the date of this filing the MOU is still active.

Transfer Agent

Our transfer agent is Transfer Online, Inc. whose address is 512 SE Salmon Street, Portland, Oregon 97214, and telephone number (503) 227-2950.

Company Contact Information

Our principal executive and subsidiary offices are located at 2020 General Booth Blvd., Unit 230, Virginia Beach, VA 23454, telephone (757) 306-6090. The information to be contained in our Internet website, www.bioforceeclipse.com, shall not constitute part of this report.

Current Directors

The following table provides information concerning our officers and directors. All directors hold office until the next annual meeting of stockholders or until their successors have been elected and qualified.

Merle Ferguson	Director
Richard Kaiser	Director/CFO/Secretary

Steve Gagnon	Co-CEO
John LaViolette	Co-CEO
Sasha Shapiro	President

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overall Operating Results:

Three Months – Three Months Ended September 30, 2025 and 2024 - Unaudited Statements

The Sales Revenue from the Company’s BioForce Eclipse vitamin supplements for the three months ended September 30, 2025 and for the three months ended September 30, 2024 were $-0- and $-0-, respectively. During the three months ended September 30, 2025 and 2024, the Company received no orders, -0- units of its Bioforce Eclipse supplement product.

The Cost of Goods Sold for the three months ended September 30, 2025 and 2024 was $-0- .

Gross Margins for the three months ended September 30, 2025 and 2024 was 0% from the sale of -0- units of the BioForce Eclipse supplement product.

Gross Profit for the three months ended September 30, 2025 and 2024 was $-0- .

Operating expenses for three months ended September 30, 2025 totaled $115,915 from Board of Director compensation and General and Administrative Expenses, compared to $122,024 for the three months ended September 30, 2024. The decrease in September 30, 2025 compared to the same period ended September 30, 2024 was attributed to lower General and Administrative Expenses.

-11-

Nine Months – September 30, 2025 and 2024 - Unaudited Statements

The Sales Revenue from the Company’s "BioForce Eclipse" vitamin supplement for the nine months ended September 30, 2025 and 2024 were $-0-, Company sold no units of its Bioforce Eclipse" vitamin supplement.

The Cost of Sales for the nine months ended September 30, 2025 and 2024 were $-0-.

Gross Margins for the nine months ended September 30, 2025 and 2024 were 0% from the sale of -0- units of the “BioForce Eclipse” supplement product.

Gross Profit for the nine months ended September 30, 2025 and 2024 were $-0-.

Operating expenses for nine months ended September 30, 2025, totaled $372,153 from Board of Director Compensation and General and Administrative Expenses, compared to $$367,277 for the nine months ended September 30, 2024. The increase in the nine months ended September 30, 2025 compared to the same period ended September 30, 2024 was attributed to higher General and Administrative Expenses

Net Loss:

Net loss for the three months ended September 30, 2025 and 2024 were $115,915 and $122,024 respectively. Net loss for the nine months ended September 30, 2025 and 2024 were $1,173,346 and $367,277, respectively. During the nine months ended September 30, 2025, the Company recorded a Loss on Liability Settlement of $801,193 from the issuance of shares to pay accrued officer and director fees (See Note 6 in Financial Statements).

Liquidity and Capital Resources:

As of September 30, 2025, the Company’s assets totaled $784 which consisted of Cash. Our total liabilities were $500,722 from accounts payable and accrued expenses, accrued director compensation expenses and amounts due to related parties. As of September 30, 2025, the Company had an accumulated deficit of $162,293,512 and working capital deficit $499,938.

For the nine months ended September 30, 2025, net cash used in operations of $54,229 was the result of a net loss for the period of $1,173,346, from an increase in loss on liability settlement of $801,193, Accounts Payables and Accrued Expenses of $1,873, an increase in Due to Related Parties of $54,151, and from an increase in accrued Board of Directors' and Officer Compensation of $316,051.

For the nine months ended September 30, 2024, net cash used in operations of $46,415 was the result of a net loss of $367,277, from an increase Accounts Payables and Accrued Expenses of $3,612, an increase in Capital Contribution of $8,075, an increase in Due to Related Parties of $39,337, and from an increase accrued Board of Director and Officer Compensation of $317,250.

As indicated herein, we need capital for the implementation of our business plan, and we will need additional capital for continuing our operations. We do not have sufficient revenues to pay our operating expenses at this time. Unless the Company is able to raise working capital, it is likely that the Company will either have to cease operations or substantially change its methods of operations or change its business plan (See Note 4 in Financial Statements).

Bio Force Innocence Holdings, Inc. does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company, or any of its subsidiaries’ operating results, financial position, or cash flow.

Cash Used In Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2025 and 2024 were $54,229 nd $46,415, respectively.

Cash Flows from Investing Activities

Net cash used in investing activities was $-0- for both the nine month periods ended September 30, 2025 and 2024.

Cash Provided by Financing Activities

Net cash provided by financing activities was $54,151 for nine months ended September 30, 2025 from the proceeds from Related Parties, and was $47,412 for nine months ended September 30, 2024 from Capital Contributions and proceeds from Related Parties.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

New Accounting Pronouncements

BioForce Nanosciences Holdings, Inc. does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company, or any of its subsidiaries' operating results, financial position, or cash flow.

-12-

Accounting Principals

Our consolidated financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. Critical accounting policies include revenue recognition and impairment of long-lived assets.

Revenue Recognition

In accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), revenues are recognized when control of the promised goods or services is transferred to our clients, in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the company satisfies a performance obligation.

We adopted this ASU on January 1, 2018. Although the new revenue standard is expected to have an immaterial impact, if any, on our ongoing net income, we did implement changes to our processes related to revenue recognition and the control activities within them.

Preferred Stock

BioForce Nanosciences Holdings, Inc. is authorized to issue 100,000,000 shares of preferred stock, par value at $0.001 per share. Based on the amended Articles of Incorporation the Company has 10,000,000 Series 'A' Preferred which have voting and conversion rights of 100 common shares, par value $0.001; leaving a balance of 90,000,000 "Blank Check" Preferred. There are no Series 'A' Preferred shares issued or outstanding.

Going Concern

We have incurred net losses since our inception. We anticipate incurring additional losses before realizing growth in revenue and we will depend on additional financing in order to meet our continuing obligations and ultimately to attain profitability. Our ability to obtain additional financing, whether through the issuance of additional equity or through the assumption of debt, is uncertain. Accordingly, our independent auditors' report on our financial statements for the year ended December 31, 2024 includes an explanatory paragraph regarding concerns about our ability to continue as a going concern, including additional information contained in the notes to our financial statements describing the circumstances leading to this disclosure. The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue our business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on our evaluation, our Principal Executive Officer and Principal Financial Officer, after considering the existence of material weaknesses identified, determined that our internal control over financial reporting disclosure controls and procedures were not effective as of September 30, 2025

Evaluation of Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with the authorization of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

-13-

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management, including our Principal Executive Officer and Principal Financial Officer, assessed the effectiveness of our internal control over financial reporting as of September 30, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in Internal Control – Integrated Framework (2013).

We identified the following deficiencies which together constitute a material weakness in our assessment of the effectiveness of internal control over financial reporting as of September 30, 2025:

- The Company has inadequate segregation of duties within its cash disbursement control design.

- During the period ended September 30, 2025, the Company internally performed all aspects of its financial reporting process, including, but not limited to the underlying accounting records and the recording of journal entries and for the preparation of financial statements. This process was deficient, because these duties were performed often times by the same people, and therefore a lack of review was created over the financial reporting process that might result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC. These control deficiencies could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control system, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

This report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management's report in this annual report.

We regularly review our system of internal control over financial reporting to ensure that we maintain an effective internal control environment. If deficiencies appear in our internal controls, management will make changes that address those deficiencies.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal control over financial reporting that occurred during the reporting period ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

At this time, there are no materials pending legal proceedings to which the Company is a party or as to which any of its property and products are subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ending September 30, 2025, the Company's Board, on January 24, 2025, approved the issuance of 4,250,000 restricted 144 shares of common stock to pay for accrued officer and director fees.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINING SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION.

A related party, on November 10, 2025, provided the Company $10,000 to pay professional service fees and other operational expenses.

-14-

ITEM 6. EXHIBITS

Index to Exhibits.

Exhibit No.		Description of Exhibit

31.1		Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.+

31.2		Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §302 of the Sarbanes-Oxley Act of 2002.+

32.1		Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.+

32.2		Certification Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002.+

101		Interactive Financial Data XBRL Extensions+

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)+

filed herewith

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this Amended report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOFORCE NANOSCIENCES HOLDINGS, INC.

Dated: November 19, 2025	By:	/s/Steve Gagnon
		Steve Gagnon
		Chief Executive Officer

	By:	/s/Richard Kaiser
		Richard Kaiser
		Chief Financial Officer, Principal Accounting Officer and Secretary

-15-

BIOFORCE NANOSCIENCES HOLDINGS, INC. 10-Q